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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S187Conclusions: These data indicate that the SCT was not responsive to
change in this cohort over 2 years, and did not adequately discriminate
between patients identiﬁed as responders or non-responders, at any
level of theWOMAC-T, WOMAC-PF or knee extensor strength criteria, in
a cohort of people with knee OA. The difference in SCT means between
responders and non-responders did not exceed SDC (90%). The SCT
failed to demonstrate construct validity for discriminating between
responders or non-responders on any level of the WOMAC-T, WOMAC-
PF or knee extensor strength criteria. SCT-down performed worse than
SCT-up. We cannot recommend the SCT as an outcome measure in
cohort studies of people with knee OA. Results may differ in trials with
protocolized interventions and shorter follow-up.
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PAIN IN ACTIVITY EVALUATION (PACE) IN KNEE OSTEOARTHRITIS –
RESPONSIVENESS AND CONCURRENT VALIDITY OF TENTATIVE
MEASURES IN A RANDOMIZED CONTROLLED EXERCISE STUDY
L. Klokker, E. Bandak, C. Bartholdy, H. Bliddal, M. Henriksen. The Parker
Inst., Frederiksberg, Denmark
Purpose: Pain and physical function are recommended outcomes in
knee osteoarthritis (OA) treatment. Patient Reported Outcome Meas-
ures (PROM) are standard, sometimes supplemented with performance
tests. Pain and function are closely related but this clinically relevant
interaction is not accounted for in existing outcome measures to knee
OA. Therefore we developed two versions of a tentative standardized
measure consisting of patient reported pain intensity after 6 and 20
minutes of walking respectively, called Pain in ACtivity Evaluation
(PACE6 and PACE20). The purposewas to investigate the responsiveness
to changes of PACE6 and PACE20 after a 12 week exercise program, and
to explore the concurrent validity of PACE6 and PACE20 against existing
measures of pain and function.Table 1
Baseline scores, changes at follow-up, differences between groups and effect sizes
EXE CON
BaselineMean
(SD)
Mean change at
follow-up* (95%CI)
BaselineMean
(SD)
Mean change at
follow-up* (95%CI)
Mean difference
(95%CI)
p-value Effect size (95% CI)
PACE20, NRS/km 18.3 (17.0) 8.3 (12.7 to 3.9) 14.2 (13.2) 1.9 (6.7 to 2.9) 6.4 (0.1 to 12.9) 0.0537 0.66 (0.43 to 0.88)
Pre 20MW pain,
0–100
12.4 (20.7) 0.3 (1.1 to 0.5) 6.4 (11.0) 0.6 (1.5 to 0.3) 0.3 (1.5 to 0.9) 0.6409 0.16 (0.06 to 0.37)
Post 20MWpain,
0–100
21.5 (26.9) 8.7 (14.9 to 2.4) 19.1 (19.3) 3.3 (10.1 to 3.5) 5.3 (3.9 to 14.6) 0.2496 0.39 (0.17 to 0.60)
PACE6, NRS/km 47.6 (39.6) 26.5 (42.7 to 10.3) 43.6 (48.2) 1.8 (15.4 to 18.9) 28.3 (4.6 to 51.9) 0.0206 0.83 (0.58 to 1.07)
Pre 6MW pain,
0–100
13.3 (17.8) 1.2 (1.8 to 0.6) 10.2 (17.4) 0.8 (1.4 to 0.1) 0.4 (0.4 to 1.3) 0.3230 0.33 (0.12 to 0.55)
Post 6MWpain,
0–100
22.3 (17) 12.5 (21.0 to 3.9) 21.5 (22.2) 2.0 (7.3 to 11.3) 14.5 (1.9 to 27.1) 0.0259 0.77 (0.51 to 1.00)
6MW, m 507.3 (99.3) 5.9 (41.0 to 52.8) 546.2 (74.9) 0.3 (50.7 to 51.3) 5.6 (75.7 to 64.5) 0.8717 0.05 (0.16 to 0.27)
KOOSpain, 0–100 55.1 (16.5) 6.8 (2.4 to 11.1) 59.0 (10.4) 1.4 (6.0 to 3.1) 8.2 (14.5 to 1.9) 0.0125 0.87 (0.64 to 1.10)
KOOSadl, 0–100 62.9 (15.6) 5.1 (0.2 to 10.0) 73.6 (13.2) 0.2 (5.0 to 5.4) 4.8 (12.2 to 2.6) 0.1919 0.44 (0.22 to 0.66)
* Adjusted for baseline values.
Table 2
Spearman correlation coefﬁcients
6MW KOOSpain KOOSadl
PACE20, NRS/km 0.271 0.588* 0.486*
Pre20MWpain, 0–100 0.079 0.505* 0.380*
Post20MWpain, 0–100 0.123 0.425* 0.297
PACE6, NRS/km 0.580* 0.357* 0.447*
Pre6MWpain, 0–100 0.484* 0.477* 0.502*
Post6MWpain, 0–100 0.467* 0.314 0.384*
*Statistical signiﬁcance level at p < 0.05.Methods: We used data from a random subgroup that completed
the PACE6 and PACE20, nested in an assessor blinded randomized
controlled trial (NCT01545258) comparing 12 weeks of supervised
exercise 3 times weekly (EXE) with a no attention control group
(CON). PACE6 is the 6-minutes walking test (6MW), i.e. walking as
fast as possible for 6 minutes, including pain rating on a 0–100
Numeric Rating Scale before (pre6MWpain) and immediately after
(post6MWpain). The PACE6 score was deﬁned as post6MWpain
divided by the distance walked in km (6MW), and scored in NRS/
km. The PACE20 score was deﬁned as pain rated on a 0–100 NRS
immediately after walking on a treadmill at a constant self-selected
comfortable speed for 20 minutes (post20MWpain), divided by the
distance walked in km, and scored in NRS/km. Pain was also rated
before the test (pre20MWpain). In PACE20 the baseline walking
speed was used at the follow-up visit. Further, the Knee injury andOsteoarthritis Outcome Score (KOOS) were assessed at baseline and
follow-up. We used the pain and activities of daily living (ADL)
subscales for this study. Effects of exercise on the outcomes were
assessed by ANCOVA adjusting for baseline values,
comparing changes from baseline between EXE and CON groups.
To explore concurrent validity of the PACE6 and PACE20 associa-
tions between all baseline parameters were assessed using Spear-
man’s rank correlation. All analyses were performed on the per
protocol population deﬁned as participants included in the RCT
analysis with complete PACE6 and PACE20 at baseline and follow-
up.
Results: A total of 37 participants deﬁned the per protocol population
(EXE ¼ 20, CON ¼ 17). Mean baseline scores of all outcomes are shown
in Table 1. There were signiﬁcant group differences in the changes in
PACE6, post6MWpain and KOOSpain in favor of EXE, but not in the other
outcomes (Table 1). Baseline scores of both PACE6 and PACE20 were
correlated to KOOSpain and KOOSadl, while only PACE6 was correlated
to the 6MW (Table 2).
Conclusions: The PACE6 was responsive to change in pain (NRS/km)
after 12 weeks of exercise and able to detect a signiﬁcant difference
between exercise and control groups. In contrast the lack of
responsiveness of pre-test pain scores supports the relevance of an
activity based pain measure. The PACE20 was less responsive,
implying that pain in activity can be assessed by one single pain
rating immediately after 6 instead of 20 minutes of walking, at least
if the speed is the fastest possible. This is a promising ﬁnding
regarding feasibility, making use of even shorter tests probable. The
associations between PACE6 and both patient reported pain and
function (KOOS), and observed performance (6MW) show concurrent
validity, and suggest that PACE6 captures both a pain and a func-
tional/performance aspect. While the PACE still needs reﬁnement
these results encourage the pursuit of developing a feasible stand-ardized measure that reﬂects the interaction between pain and
function.
